Risk Stratification of Pubertal Children and Postpubertal Adolescents with Clinical Stage I Testicular Nonseminomatous Germ Cell Tumors

被引:13
|
作者
Cost, Nicholas G. [1 ,3 ]
Lubahn, Jessica D. [1 ]
Adibi, Mehrad [1 ]
Romman, Adam [1 ]
Wickiser, Jonathan E. [2 ]
Raj, Ganesh V. [1 ]
Sagalowsky, Arthur I. [1 ]
Margulis, Vitaly [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Div Urol Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Div Pediat Oncol, Dallas, TX 75390 USA
[3] Univ Colorado, Sch Med, Div Urol, Aurora, CO 80045 USA
关键词
testis; neoplasms; germ cell and embryonal; neoplasm metastasis; adolescent; puberty; LYMPH-NODE DISSECTION; ADJUVANT CHEMOTHERAPY; CANCER; TESTIS; METASTASES; RELAPSE;
D O I
10.1016/j.juro.2013.08.047
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The COG (Children's Oncology Group) currently recommends surveillance for all children and adolescents with clinical stage I testicular germ cell tumors. However, up to 30% of adults with clinical stage I testicular germ cell tumors harbor occult metastatic disease. In adults with clinical stage I nonseminoma some groups advocate a risk stratified approach. Occult metastases were noted in 50% of patients with features such as lymphovascular invasion or embryonal carcinoma predominance in the orchiectomy. However, to our knowledge there are no data on the impact of high risk features in such pubertal children and postpubertal adolescents. Materials and Methods: We reviewed an institutional testis cancer database for pubertal children and postpubertal adolescents younger than 21 years. We tested the hypothesis that lymphovascular invasion, or 40% or greater embryonal carcinoma in the orchiectomy specimen, would increase the risk of occult metastases, ie relapse during surveillance or positive nodes on retroperitoneal lymph node dissection. Results: We identified 23 patients with a median age of 18.6 years (range 7.1 to 20.9) at diagnosis. Of these patients 14 (60.9%) were on surveillance, 9 (39.1%) underwent primary retroperitoneal lymph node dissection and none received initial chemotherapy. Seven patients (30.4%) had occult metastatic disease. High risk pathological features were found in the orchiectomy specimen in 12 patients (52.2%), including all 12 (52.2%) with 40% or greater embryonal carcinoma and 3 (13.0%) with lymphovascular invasion. Seven patients (58.3%) with high risk features had occult metastatic disease vs none (0%) without high risk features (log rank p = 0.031). Conclusions: Approximately half of pubertal children and postpubertal adolescents with high risk clinical stage I testicular germ cell tumors harbor occult metastatic disease. These results may be useful when discussing prognosis and treatment with patients and families.
引用
收藏
页码:1485 / 1490
页数:6
相关论文
共 50 条
  • [21] A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only
    Nicolai, N
    Miceli, R
    Artusi, R
    Piva, L
    Pizzocaro, G
    Salvioni, R
    JOURNAL OF UROLOGY, 2004, 171 (01) : 172 - 176
  • [22] Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis
    Nguyen, Carvell T.
    Fu, Alex Z.
    Gilligan, Timothy D.
    Wells, Brian J.
    Klein, Eric A.
    Kattan, Michael W.
    Stephenson, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 119 - 125
  • [23] Management of patients with clinical stage I nonseminomatous germ cell testicular cancer: Active surveillance versus adjuvant chemotherapy - single-centre experience
    Ondrus, D.
    Ondrusova, M.
    Kajo, K.
    NEOPLASMA, 2015, 62 (01) : 159 - 163
  • [24] Surveillance Results of Patients with Stage I Nonseminomatous Germ Cell Testicular Cancer
    Keskin, Serkan
    Ekenel, Meltem
    Basaran, Mert
    Bavbek, Sevil
    ONKOLOGIE, 2011, 34 (04): : 173 - 176
  • [25] Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis
    Westermann, Dirk H.
    Schefer, Hubert
    Thalmann, George N.
    Karamitopoulou-Diamantis, Evanthia
    Fey, Martin F.
    Studer, Urs E.
    JOURNAL OF UROLOGY, 2008, 179 (01) : 163 - 166
  • [26] Non-Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital's Experience
    Sturgeon, Jeremy F.
    Moore, Malcolm J.
    Kakiashvili, David M.
    Duran, Ignacio
    Anson-Cartwright, Lynn C.
    Berthold, Dominik R.
    Warde, Padraig R.
    Gospodarowicz, Mary K.
    Alison, Ruth E.
    Liu, Justin
    Ma, Clement
    Pond, Greg R.
    Jewett, Michael A.
    EUROPEAN UROLOGY, 2011, 59 (04) : 556 - 562
  • [27] Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours
    Pedraza, Adriana M.
    Stephenson, Andrew J.
    CURRENT OPINION IN UROLOGY, 2018, 28 (05) : 448 - 453
  • [28] Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors -: Is shift to risk adapted policy justified?
    Divrik, Rauf Taner
    Akdogan, Buelent
    Ozen, Haluk
    Zorlu, Ferruh
    JOURNAL OF UROLOGY, 2006, 176 (04) : 1424 - 1429
  • [29] Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors
    Yetisyigit, Tarkan
    Babacan, Nalan
    Urun, Yuksel
    Seber, Erdogan Selcuk
    Cihan, Sener
    Arpaci, Erkan
    Yildirim, Nuriye
    Aksoy, Sercan
    Budakoglu, Burcin
    Zengin, Nurullah
    Oksuzoglu, Berna
    Yalcin, Banu Cicek
    Alkis, Necati
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (02) : 831 - 835
  • [30] SIGNIFICANCE OF ANEUPLOID STEMLINES IN TESTICULAR NONSEMINOMATOUS GERM-CELL TUMORS
    DEGRAAFF, WE
    SLEIJFER, DT
    DEJONG, B
    DAM, A
    KOOPS, HS
    OOSTERHUIS, JW
    CANCER, 1993, 72 (04) : 1300 - 1304